 |
|
|
| |
MK-3682B Is Not a Clinically Significant CYP3A Inhibitor or Inducer
|
| |
| |
Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy; Chicago, IL, USA; June 14-16, 2017.
Nancy Kim1*; Wei Gao1; Leticia Arrington1; Xiaoli Shirley Glasgow1; Graig Garrett1; Matthew L. Rizk1; Deborah Panebianco1; Heather Jordan2; Antonios Aliprantis1; Marian Iwamoto1
1Merck & Co., Inc., Kenilworth, NJ, USA; 2Pharma Medica Research Inc., St. Charles, MO, USA
*Corresponding author
|
| |
|
|
|
|
|
